European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe

⏳ Only 7 days left to share your input The EDQM stakeholder survey for the 2028–2031 Mid-Term Strategy will close soon and this is your opportunity to help shape our future direction. ➡️ https://lnkd.in/dgSmuzb8 ⏱️ Takes just 10 minutes 🔒 Responses remain confidential 🔴 Deadline: 20 August 2026 Share your views on: ⭐ Future priorities; ⭐ Emerging challenges and opportunities; ⭐ Key strategic choices; ⭐ How the EDQM engages and collaborates with its stakeholders. #TogetherForBetterHealthForAll 💪

🔆 Longer days, brighter ideas: take #EDQMonAir with you this summer. In this episode, our guests provide insights into EDQM’s impact across various sectors: ➡️ Salvador Cañigueral, former Chair of the European Pharmacopoeia Commission #EPC ➡️ Massimiliano Conti, former Chair of the GEON Advisory Group #OMCL ➡️ Anne Garnier, Scientific Programme Manager at EDQM’s European Pharmacopoeia Department ➡️ Marie Laure Hecquet, EDQM Policy Advisor Gain a behind-the-scenes look at EDQM's role in the European public health landscape and how it collaborates with health bodies to ensure better health outcomes for all. 🎧 Listen now on all major podcast platforms: https://lnkd.in/e4X2JuNs #TogetherForBetterHealth 💪

We continue to advance public quality standards for plasma-derived medicinal products with the adoption of a new European Pharmacopoeia (Ph. Eur.) general chapter, 2.6.42 – Test for procoagulant activity in immunoglobulin preparations, which will enter into force on 1 July 2027. Published in Ph. Eur. Issue 13.3 (October 2026), the chapter introduces three methods for the detection of procoagulant activity: a factor XIa-specific chromogenic substrate assay (CSA), alongside thrombin generation (TGA) and NAPTT assays. Together, these methods support the detection of potential procoagulant impurities that may affect product safety. Developed through collaborative scientific studies, this new text reflects our ongoing commitment to standardised, science-based methods that help ensure the quality, safety and efficacy of human immunoglobulin products across Europe. Learn more ➡️ https://lnkd.in/d6B3HGRt #TogetherForBetterHealthForAll 💪

⏳ Only 14 days left to share your input The EDQM stakeholder survey for the 2028–2031 Mid-Term Strategy will close soon and this is your opportunity to help shape our future direction. ➡️ https://lnkd.in/dgSmuzb8 ⏱️ Takes just 10 minutes 🔒 Responses remain confidential 🔴 Deadline: 20 August 2026 Share your views on: ⭐ Future priorities; ⭐ Emerging challenges and opportunities; ⭐ Key strategic choices; ⭐ How the EDQM engages and collaborates with its stakeholders. hashtag #TogetherForBetterHealthForAll 💪

Contamination and deliberate adulteration involving ethylene glycol (EG) and diethylene glycol (DEG) continue to present significant risks to patient safety worldwide. To support the detection and control of these toxic contaminants, a new analytical procedure for the determination of EG and DEG in Macrogols (Ph. Eur. monograph 1444) has been published in Pharmeuropa 38.3 for public consultation. The proposed revision introduces: ✅ A new gas chromatography procedure using an alternative stationary phase; ✅ A derivatisation step and internal standard approach; ✅ Revised specifications with individual limits for EG and DEG. These enhancements aim to strengthen analytical robustness and support the continued quality and safety of pharmaceutical excipients used in medicines. 🔴 Deadline: 30 September 2026 Read more 👉 https://lnkd.in/dQDfGNum #TogetherForBetterHealthForAll 💪

🩸 Human plasma is essential to make life-saving medicines for people with rare, chronic and life-threatening conditions. However plasma collection in Europe remains insufficient to meet growing demand, resulting in a heavy reliance on imports and exposing patients to potential supply vulnerabilities. To support member states in addressing this public health challenge, the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe has published a meeting report providing a comprehensive overview of the discussions and outcomes of the meeting "Plasma Supply Continuity stakeholder event" in Strasbourg on 26-27 March 2025. ➡️ https://lnkd.in/eY7uVFHs

🔆 Wherever summer takes you, take #EDQMonAir along. Artificial intelligence is transforming healthcare, from faster diagnostics to reducing administrative burdens for medical professionals. But how do we ensure responsible AI use while protecting patient data and privacy? Can we really entrust our health to machines? In this episode, Eric Sutherland, Senior Health Economist OECD - OCDE, shares his insights on digital health, policy guidance & responsible AI analytics. 🎧 Tune in now and explore the EDQM’s impact! https://lnkd.in/eK-mv57r #TogetherForBetterHealthForAll 💪

We have introduced a new feature in the CEP database that enables users to download the complete dataset relating to Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs). Read more ➡️ https://lnkd.in/d-Bj8cpA #TogetherForBetterHealthForAll 💪

On 28 January 2027, we will host an in-person hearing in Strasbourg, France, dedicated to the future of excipient standards in the European Pharmacopoeia (Ph. Eur.). This event is a unique opportunity for stakeholders to provide feedback on the draft recommendations developed by the Excipients Strategy Working Party (EXS WP) before they are finalised and submitted to the EPC for adoption as the Ph. Eur. Excipient Strategy. Further information on the programme and registration will be shared in the coming months. Read more https://lnkd.in/dkjkQj-h #TogetherForBetterHealthForAll 💪